The stock has jumped 1.5 percent in the early morning deals on the BSE.
Lupin started the day on positive note on the BSE, after the media reported that the firm received USFDA approval for generic Exforge HCT, which is a blood pressure medicine.
The stock is now up 1 percent at Rs. 1,764. Around 0.15 shares are traded on the BSE, as against two-week daily average volume of 146,000 shares.
Meanwhile, the Sensex has declined 64 points at 26,785.
Lupin started the day on positive note on the BSE, after the media reported that the firm received USFDA approval for generic Exforge HCT, which is a blood pressure medicine.
The stock is now up 1 percent at Rs. 1,764. Around 0.15 shares are traded on the BSE, as against two-week daily average volume of 146,000 shares.
Meanwhile, the Sensex has declined 64 points at 26,785.
No comments:
Post a Comment